

ZIMBABWE – PENTAVALENT VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Zimbabwe			
2. Grant Number: 0815-ZWE-04c-X			
3. Date of Decision Letter: 23 January 2015			
4. Date of the Partnership Framework Agreement: 17 May 2013			
5. Programme Title: New Vaccine Support			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID			
8. Programme Duration⁶: 2008 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2008-2014	2015	Total ⁷
Programme Budget (US\$)	US\$24,568,651 ⁸	US\$2,297,500	US\$26,866,151
10. Vaccine Introduction Grant: Not applicable			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁹			
Type of supplies to be purchased with Gavi funds in each year	2008-2014	2015	
Number of Pentavalent vaccines doses		1,127,000	
Number of AD syringes		1,214,000	
Number of safety boxes		13,375	
Annual Amounts (US\$)	US\$24,568,651 ¹⁰	US\$2,297,500	
12. Procurement agency: UNICEF			

⁶ This is the entire duration of the programme.

⁷ This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

⁸ This is the consolidated amount for all previous years.

⁹ This is the amount that Gavi has approved.

¹⁰ This is the consolidated amount for all previously approved years.

13. Self-procurement: Not applicable	
14. Co-financing obligations: Reference code: 0815-ZWE-04c-X-C	
According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.	
Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	127,000
Value of vaccine doses (US\$)	US\$242,559
Total Co-Financing Payments (US\$) (including freight)	US\$251,000
15. Operational support for campaigns: n/a	
16. Additional documents to be delivered for future disbursements:	
Reports, documents and other deliverables	Due dates
Annual Progress Report or its equivalent	15 May 2015
17. Financial Clarifications: Not applicable	
18. Other conditions: Not applicable	

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
23 January 2015

ZIMBABWE - PNEUMOCOCCAL VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Zimbabwe				
2. Grant Number: 1216-ZWE-12c-X				
3. Date of Decision Letter: 23 January 2015				
4. Date of the Partnership Framework Agreement: 17 May 2013				
5. Programme Title: New Vaccine Support				
6. Vaccine type: Pneumococcal				
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID				
8. Programme Duration ¹ : 2012 - 2016				
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):				
	2012-2014	2015	2016	Total ²
Programme Budget (US\$)	US\$22,855,189 ³	US\$5,268,000	US\$5,198,500	US\$33,321,689
10. Vaccine Introduction Grant: Not applicable				
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴				
Type of supplies to be purchased with Gavi funds in each year	2012-2014	2015		
Number of Pneumococcal vaccines doses		1,245,600		
Number of AD syringes		1,376,000		
Number of safety boxes		15,150		
Annual Amounts (US\$)	US\$22,855,189 ⁵	US\$5,268,000		
12. Procurement agency: UNICEF				

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years.

13. Self-procurement: Not applicable		
14. Co-financing obligations: Reference code: 1216-ZWE-12c-X-C		
According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.		
Type of supplies to be purchased with Country funds in each year	2015	2016
Number of vaccine doses	75,600	84,600
Value of vaccine doses (US\$)	US\$249,454	
Total Co-Financing Payments (US\$) (including freight)	US\$264,500	US\$301,500
15. Operational support for campaigns: Not applicable		
16. Additional documents to be delivered for future disbursements:		
Reports, documents and other deliverables	Due dates	
Annual Progress Report or its equivalent	15 May 2015	
17. Financial Clarifications: Not applicable		
18. Other conditions: Not applicable		

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
23 January 2015

ZIMBABWE – ROTAVIRUS VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Zimbabwe				
2. Grant Number: 1316-ZWE-13b-X				
3. Date of Decision Letter: 23 January 2015				
4. Date of the Partnership Framework Agreement: 17 May 2013				
5. Programme Title: New Vaccine Support				
6. Vaccine type: Rotavirus				
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule				
8. Programme Duration¹¹: 2013 - 2016				
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):				
	2013-2014	2015	2016	Total ¹²
Programme Budget (US\$)	US\$2,636,779 ¹³	US\$2,016,000	US\$2,527,500	US\$7,180,279
10. Vaccine Introduction Grant: Not applicable				
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):¹⁴				
Type of supplies to be purchased with Gavi funds in each year	2013-2014	2015		
Number of Rotavirus vaccines doses		757,500		
Annual Amounts (US\$)	US\$2,636,779 ¹⁵	US\$2,016,000		
12. Procurement agency: UNICEF				
13. Self-procurement: Not applicable				

¹¹ This is the entire duration of the programme.

¹² This is the total amount endorsed by Gavi for the entire duration of the programme. This should be equal to the total of all sums in the table.

¹³ This is the consolidated amount for all previous years.

¹⁴ This is the amount that Gavi has approved.

¹⁵ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 1316-ZWE-13b-X-C

According to the Co-Financing Policy, the Country falls within the group Low Income. The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015	2016
Number of vaccine doses	60,000	75,000
Value of vaccine doses (US\$)	US\$153,682	
Total Co-Financing Payments (US\$) (including freight)	US\$160,000	US\$201,000

15. Operational support for campaigns: Not applicable

16. Additional documents to be delivered for future disbursements:

Reports, documents and other deliverables	Due dates
Annual Progress Report or its equivalent	15 May 2015

17. Financial Clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
23 January 2015